Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 1251 - 1275 of 2259 in total
Delpacibart is a humanized, bispecific, bivalent monoclonal antibody against coagulation factor 9.
Investigational
Matched Description: … Delpacibart is a humanized, bispecific, bivalent monoclonal antibody against coagulation factor 9. …
LYT-200 is a fully human IgG4 monoclonal antibody directed against galectin-9.
Investigational
Matched Description: … LYT-200 is a fully human IgG4 monoclonal antibody directed against galectin-9. …
Cannabinol (CBN) is a physiologically inactive constituent of Cannabis sativa.
Experimental
Investigational
CTX110 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD19 antigen.
Investigational
CTX130 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD70 antigen.
Investigational
105AD7 is a human monoclonal antibody that mimics the complement regulatory protein, CD55, overexpressed by many solid tumours including osteosarcoma. 105AD7 induced antitumour inflammatory responses in metastatic colorectal cancer patients. 105AD7 may be a suitable vaccine for treatment of this disease.
Investigational
Pexelizumab is a humanized monoclonal antibody used as an immunosuppressive drug. It is being investigated by Alexion Pharmaceuticals.
Investigational
Rimiducid is a lipid-permeable tacrolimus analogue and a protein dimerizer. It was designed to overcome limitations of current cellular immunotherapies used for cancer and other blood disorders by enhancing the control of the immune cell activity and function. When administered via chemically-inducible dimerization (CID) technologies, rimiducid binds to switch proteins...
Investigational
Investigational
Experimental
Matched Iupac: … 7-chloro-11,17-dioxa-2,4,20,22-tetraazatricyclo[16.3.1.0^{5,10}]docosa-1(22),5(10),6,8,18,20-hexaen-3 …
Elraglusib is under investigation in clinical trial NCT04218071 (Actuate 1901: 9-ING-41 in Myelofibrosis).
Investigational
Matched Description: … Elraglusib is under investigation in clinical trial NCT04218071 (Actuate 1901: 9-ING-41 in Myelofibrosis …
Vidutolimod is a Toll-like receptor 9 (TLR9) agonist. It is an investigational cancer vaccine.
Investigational
Matched Description: … Vidutolimod is a Toll-like receptor 9 (TLR9) agonist. It is an investigational cancer vaccine. …
Perospirone is an atypical or second-generation antipsychotic of the azapirone family that antagonizes serotonin 5HT2A receptors and dopamine D2 receptors. It also displays affinity towards 5HT1A receptors as a partial agonist. Dainippon Sumitomo Pharma developed perospirone in Japan in 2001 for the treatment of acute schizophrenia and bipolar mania as...
Experimental
Palazestrant is under investigation in clinical trial NCT06016738 (OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer).
Investigational
TSHA-102 is a recombinant serotype 9 adeno-associated virus encoding a codon-optimized human MECP2 gene.
Investigational
Matched Description: … TSHA-102 is a recombinant serotype 9 adeno-associated virus encoding a codon-optimized human MECP2 gene …
CTX120 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting B-cell maturation antigen.
Investigational
A version of tabituximab barzuxetan radiolabeled with yttrium-90.
Investigational
TSHA-105 is an adeno-associated virus serotype 9 (AAV9) vector with an engineered transgene encoding the human SLC13A5 protein.
Investigational
Matched Description: … TSHA-105 is an adeno-associated virus serotype 9 (AAV9) vector with an engineered transgene encoding …
NGN-101 is an adeno-associated virus serotype 9 vector with engineered transgene encoding the human CLN5 gene
Investigational
Matched Description: … NGN-101 is an adeno-associated virus serotype 9 vector with engineered transgene encoding the human CLN5 …
Displaying drugs 1251 - 1275 of 2259 in total